Cadila Healthcare's third quarter profit is expected to jump 33.2 percent year-on-year to Rs 375.6 crore and revenue is seen rising 12 percent to Rs 2,447.4 crore, according to analysts polled by CNBC-TV18. Earnings will be announced on February 5.
Revenue growth is likely to be led by 12-14 percent Y-o-Y growth in US formulations while sequential US growth may remain flat due to no US launch during the quarter.
According to analysts, withdrawal of Warfarin (an anticoagulant used to to prevent heart attacks, strokes, and blood clots) in the US and possible impact of price erosion in likes hydroxychloroquibe sulphate (HCQs - used for arthritis, lupus etc) may weigh on earnings. Domestic growth is likely to be 10-14 percent YoY.
Bottomline was supported by other income and operational performance. Operating profit (earnings before interest, tax, depreciation and amortisation) in Q3 may increase 26 percent to Rs 563 crore and margin may expand 260 basis points to 23 percent compared to year-ago period due to better business mix.
Key factors to watch out for would be commentary on warning letter for Moraiya facility and overall guidance post warning letter.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
